Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
endostar + icotinib
- Development stage
- Phase 3
- Lead developer
- Betta Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Endostar + icotinib is a combination therapy used primarily in the treatment of non-small cell lung cancer (NSCLC). Endostar (recombinant human endostatin) is an antiangiogenic biologic that inhibits tumor blood vessel formation, while icotinib is a small molecule tyrosine kinase inhibitor that selectively targets the epidermal growth factor receptor (EGFR), blocking its ATP binding site and inhibiting downstream signaling pathways involved in tumor proliferation. The combination has demonstrated enhanced antitumor efficacy compared to monotherapy, particularly by reducing microvessel density and VEGFA expression in tumors. Icotinib was developed by Betta Pharmaceuticals and is approved for EGFR-mutant NSCLC in China[2][6][8].
- Brand names
- Conmana
- Other names
- recombinant human endostatinicotinib hydrochloride
02
Targets
Beyond the preview
Go deeper on endostar + icotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on endostar + icotinib.